Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=27209 Iomed Inc.(IOX [Amex]). STOCK FOR EVERYONE! <G>(Subject title rejects <G>) web site: iomed.com (no info about new technologies yet) Now Bid 2 Ask 2 1/4 For everyone <G> investors with financ background should feel good: Price/Cash=0.8 (Not so optimistic, "potential" at least 900K (+ 200K more) shares are not included; still about 1). Of course, price is below book. Real products, real sales, revenues. Operation history from 1974. biotech optimist should feel great: small molecules delivery: oligonucleotides (related to antisense tech) genes delivery (be careful here, it's not gene delivery in today gene therapy meaning, but there is some potential relation.) anti-angiogenic compounds add proteins to that, not bad program <G>. BTW, they are selling on line, clearly, internet company. And symbol... almost IOM, but even better. IOX definitely means it will be I0 times more expensive soon <G>. About new tech, please, read: biz.yahoo.com "Ocular Delivery IOMED is also refining prototype systems for the iontophoretic delivery of therapeutics into the eye. In in-vivo studies conducted in rabbits, the Company has been successful in demonstrating the delivery of small molecules,oligonucleotides, peptides, proteins and genes through the sclera (white of the eye) and into the retina. IOMED is currently screening anti-angiogenic compounds, which would prevent the proliferation of new blood vessels in the eye, for the treatment of age-related macular degeneration and diabetic retinopathy. Both diseases, which affect the retina, are common causes of blindness and there are no approved drug therapies for the treatment of either disease. ''The need to use needle injections to get many drug candidates into the eye significantly inhibits the ability to conduct effective clinical trials in the treatment of these and other diseases of the eye,'' stated Mr. Hamilton. ''We believe that a safe and effective iontophoretic drug delivery platform could offer the pharmaceutical industry a rapid, non-invasive alternative for the delivery of therapeutics to the eye without the risk of infection, bleeding, retinal detachment or retinal tissue damage''. Does it work? Who cares! <G>(Well,at least there are very interesting possibilities. Let's hope procedure is effective, not too painful/unpleasant and may be combined with some others). Even if small percentage of such claims are correct and at least one of the methods works, market is huge. I am not aware of any medical/scientific publication from the Company that may support such claims, however. If you are not familiar with "Ionophoresis", which is, actually, electrophoresis, please, read this: "IONTOPHORETIC DRUG DELIVERY AND ITS ADVANTAGES Iontophoretic drug delivery systems are designed to overcome many of the limitations associated with many other drug delivery methods. Iontophoresis is an active method of transdermal drug delivery in which water-soluble, ionized (electrically charged)...https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=2720938013210